Premises and purpose of the study: In addition to improvement of glycemic control, oral semaglutide has favourable effects on metabolic profile of diabetic patients; several data suggest other positive metabolic actions of this drug, i.e. better control of blood pressure and amelioration of cardiovascular risk. Till now kidney function is thought to be little conditioned by oral semaglutide, although injectable semaglutide is under investigation for possible nephro-protective effects, including reduction of microalbuminuria and stabilization of renal function. In this observational study we evaluate the consequences of 12 months treatment with oral semaglutide on renal function, microalbuminuria and main CVD risk factors in 82 type 2 diabetes outpatients, on stable hypoglycemic, anti- hypertensive and/or lipid lowering therapy Materials and methods: Clinical and anthropometric data, microalbuminuria, creatinine, metabolic and lipid profile, as well as Visceral Adiposity Index, TYG index and LAP Index were measured in all the patients at baseline and after 12 months of therapy with oral semaglutide Results: Treatment with oral semaglutide was associated with significant lowering (p<0,001) from baseline values of microalbuminuria, creatinine, FBG, HbA1c, body weight, BMI, WC, LDL cholesterol, triglycerides, systolic and diastolic blood pressure, VAI, TYG index, LAP index. Significant (p<0,001) elevation was observed for the values of HDL cholesterol and EGFR Conclusions: In this study population 12-month treatment with oral semaglutide in add-on to on-going hypoglycemic therapy significantly improves renal function also reducing levels of microalbuminuria and cutting down all main CVD risk factors and cardiometabolic risk scores.